Needham analyst Joseph Stringer has maintained their bullish stance on IONS stock, giving a Buy rating on October 27.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Stringer has given his Buy rating due to a combination of factors that highlight Ionis Pharmaceuticals’ strong financial performance and positive future outlook. The company reported third-quarter revenues of $157 million, surpassing both the analyst’s expectations and the consensus estimates. This was driven by better-than-expected revenues from key products like Spinraza and Tryngolza, indicating robust demand and effective market penetration.
Furthermore, Ionis Pharmaceuticals has raised its financial guidance for 2025, projecting total revenues between $875 million and $900 million, an increase from previous estimates. This optimistic outlook is supported by recent positive Phase 3 data for zilganersen and an anticipated higher market penetration for Wainua in the ATTR-CM segment. These factors collectively contribute to the positive sentiment and justify the Buy rating assigned by Joseph Stringer.
In another report released on October 27, Oppenheimer also maintained a Buy rating on the stock with a $90.00 price target.